A randomized, double-blind, placebo-controlled phase I/II evaluation of 9-[2-(bispivaloyloxy-methyl) phosphonyl-methoxy]adenine (bis-POM PMEA), an orally bioavailable prodrug of the anti-HIV nucleotide, PMEA
- 1 March 1995
- journal article
- abstracts
- Published by Elsevier in Antiviral Research
- Vol. 26 (3) , A229
- https://doi.org/10.1016/0166-3542(95)94707-9
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: